Edition:
United States

Intersect ENT Inc (XENT.OQ)

XENT.OQ on NASDAQ Stock Exchange Global Market

32.50USD
13 Dec 2017
Change (% chg)

-- (--)
Prev Close
$32.50
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
58,983
52-wk High
$34.40
52-wk Low
$11.00

Latest Key Developments (Source: Significant Developments)

‍James Flynn​ reports 5.92 pct passive stake in Intersect ENT
Thursday, 16 Nov 2017 02:31pm EST 

Nov 16 (Reuters) - Intersect Ent Inc ::‍James Flynn​ reports 5.92 percent passive stake in Intersect ENT as of Nov 6 - SEC filing.  Full Article

FDA performs pre-approval inspection of Intersect ENT's menlo park facility
Monday, 6 Nov 2017 08:00am EST 

Nov 6 (Reuters) - Intersect ENT Inc :FDA performs pre-approval inspection of Intersect ENT's menlo park facility.Intersect ENT Inc - ‍FDA has set a pdufa target action date of January 7, 2018​.Intersect ENT Inc - ‍at conclusion of inspection, FDA issued a form 483 with four inspectional observations​.Intersect ENT Inc - does not expect inspectional observations to impact timeline for a decision from FDA on approval of sinuva implant​.  Full Article

Intersect ENT Inc reports Q3 revenue $22.3 million
Thursday, 2 Nov 2017 04:05pm EDT 

Nov 2 (Reuters) - Intersect ENT Inc :Intersect ENT Inc reports third quarter 2017 results.Q3 revenue $22.3 million versus I/B/E/S view $21.5 million.Sees q4 2017 revenue $27.3 million to $27.8 million.Intersect ENT Inc - ‍outlook for 2017 gross margin continues to be about 84%​.Intersect ENT Inc - ‍for full year 2017 expects revenue in range of $94.1-$94.6 million​.  Full Article

Intersect ENT qtrly net loss per share $0.08
Tuesday, 1 Aug 2017 04:05pm EDT 

Aug 1 (Reuters) - Intersect ENT Inc :Intersect ENT reports second quarter 2017 results.Q2 revenue $24 million versus I/B/E/S view $22.6 million.Sees Q3 2017 revenue $21 million to $21.5 million.Sees FY 2017 revenue $91 million to $93 million.Qtrly net loss per share, basic and diluted $0.08.Q2 earnings per share view $-0.19 -- Thomson Reuters I/B/E/S.Intersect ENT Inc says company continues to expect full year 2017 gross margin of approximately 84% and operating expenses in range of $96-$98 million.FY2017 revenue view $90.4 million -- Thomson Reuters I/B/E/S.Q3 revenue view $20.9 million -- Thomson Reuters I/B/E/S.  Full Article

Intersect ENT says U.S. FDA has accepted NDA for its investigational Sinuva steroid releasing sinus implant
Monday, 22 May 2017 07:00am EDT 

May 22 (Reuters) - Intersect Ent Inc :Intersect ENT Inc says U.S. FDA has accepted new drug application for company's investigational Sinuva™ steroid releasing sinus implant.Intersect ENT Inc says U.S. FDA set a PDUFA target action date of January 7, 2018.  Full Article

Intersect Ent Q1 revenue $20.5 million
Tuesday, 2 May 2017 04:05pm EDT 

May 2 (Reuters) - Intersect Ent Inc :Intersect Ent reports first quarter 2017 results.Q1 revenue $20.5 million versus i/b/e/s view $19.4 million.Sees q2 2017 revenue $22.5 million to $22.7 million.Sees fy 2017 revenue $89 million to $91 million.Qtrly net loss per share, basic and diluted $0.23.Q1 earnings per share view $-0.25, revenue view $19.4 million -- Thomson Reuters I/B/E/S.Q2 revenue view $21.7 million -- Thomson Reuters I/B/E/S.Fy2017 revenue view $88.0 million -- Thomson Reuters I/B/E/S.  Full Article

Intersect ENT submits new drug application to FDA for office-based resolve steroid releasing implant for recurrent chronic sinus disease
Wednesday, 8 Mar 2017 08:00am EST 

Intersect ENT Inc : Intersect ENT submits new drug application to FDA for office-based resolve steroid releasing implant for recurrent chronic sinus disease . Intersect ENT - Trial met both co-primary efficacy endpoints, demonstrating a statistically significant reduction in nasal congestion and polyp burden .Intersect ENT Inc - Submission supported by four clinical studies evaluating safety and effectiveness.  Full Article

Intersect Ent Q4 loss per share $0.17
Tuesday, 28 Feb 2017 04:05pm EST 

Intersect Ent Inc : Intersect ENT reports fourth quarter and full year 2016 results . Q4 loss per share $0.17 . Q4 earnings per share view $-0.19 -- Thomson Reuters I/B/E/S . Sees q1 revenue $19 million to $19.5 million . Sees fy 2017 revenue $87 million to $89 million . Q4 revenue $24.2 million versus i/b/e/s view $23.5 million . Intersect ent inc says expects full year 2017 gross margin of approximately 83%-84% and operating expenses of approximately $96-$98 million .Fy2017 earnings per share view $-0.69, revenue view $87.6 million -- Thomson Reuters I/B/E/S.  Full Article

Intersect ENT says FDA approves steroid releasing implant Propel Contour
Friday, 24 Feb 2017 08:00am EST 

Intersect Ent Inc : Intersect ENT announces FDA approval of newest steroid releasing implant, Propel Contour, for use in treating the frontal and maxillary sinuses . Intersect ENT Inc - expects to launch propel contour broadly in Q2 of 2017 and maintains its previously stated 2017 revenue guidance of $87-$89 million .FY2017 revenue view $88.0 million -- Thomson Reuters I/B/E/S.  Full Article

Intersect Q2 loss per share $0.21
Tuesday, 2 Aug 2016 04:05pm EDT 

Intersect ENT Inc : Q2 loss per share $0.21 . Q2 revenue $19.3 million versus I/B/E/S view $18.8 million . Intersect ENT reports second quarter 2016 results . Q2 earnings per share view $-0.26 -- Thomson Reuters I/B/E/S . Sees Q3 2016 revenue about $17.8 million . Fy2016 revenue view $78.3 million, q3 revenue view $18.4 million -- Thomson Reuters I/B/E/S .Expects full year revenue at low end of previous guidance range of $78 million-$80 million.  Full Article

BRIEF-‍James Flynn​ reports 5.92 pct passive stake in Intersect ENT

* ‍James Flynn​ reports 5.92 percent passive stake in Intersect ENT as of Nov 6 - SEC filing Source text : (http://bit.ly/2jwmJXW) Further company coverage: